Rubella Vaccine Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2020 - 2025

Report Code: HCR 90356 Report Format: PDF + Excel (Delivery in 48 Hrs)
Rubella Vaccine Market size is forecast to reach 4.3 billion by 2025, growing at a CAGR of 6.07 during the forecast period 2020-2025. Rubella is a contagious infection which  is caused  by the transmission of  airborne droplets of infected people through coughing or sneezing. Increase  in the incidence of rubella infection and increase in the infection which results in congenital defects known as congenital rubella syndrome are the major factors driving the growth of the market is set to further enhance the overall market demand of rubella vaccine  during the forecast period 2020-2025. 

Report Coverage
The report: “Rubella Vaccine Market Forecast (2019-2025)”, by IndustryARC, covers an in-depth analysis of the following segments of the Rubella Vaccine Market. 

By End User: Pediatric Rubella Vaccine, Adult Rubella Vaccine and Traveler Rubella Vaccine
By Application:  Hospital Pharmacies, Drug Stores and Retail Pharmacies
By Geography: North America, Europe, Asia Pacific, and Rest of the World.

Key Takeaways
  • North America dominates the Rubella Vaccine Market owing to growing initiatives for immunization against diseases. The Rubella Vaccine Market scope for different regions will be provided in the final report.
  • Rising air pollution and increase in governments focus on rubella vaccination   is likely to aid in the market growth of rubella vaccine market
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Rubella Vaccine Market report.
  • Reactions related to vaccinations and insufficient yield is set to create hurdles for the Rubella Vaccine Market.

End User- Segment Analysis
Rubella is a severe and infectious disease triggered by a virus. Pediatric vaccines are given in two doses. First at the age of 15 months and second is before the age of six. Pediatric vaccines are more effective than adult vaccines. Adult vaccine is only single dose vaccine. Both vaccines contain small amounts of neomycin and gelatin. They are supplied as a lyophilized (freeze-dried) powder with a separate diluent. Pediatric Vaccines is forecast to be the fastest growing with a CAGR of 7.15% during the forecast period 2020-2025. This is owing to the growing initiatives for immunization against diseases.

Application - Segment Analysis
Hospital Pharmacies dominates the rubella vaccine market owing to  growing industrialization which is leading to propel the airborne diseases globally and the symptoms related to airborne diseases include fever, cough, redness in the eyes and running nose coupled with rashes in the body. Increase in the success rate of vaccination schemes depends on government initiatives of each country. Rubella vaccine is also used in drug stores and retail pharmacies. Hospital pharmacies is set to be the fastest growing segment of the rubella vaccine market during the forecast period 2020-2025.

Geography - Segment Analysis
North America dominates  the rubella vaccine   market with a share of more than 37.1%, followed by Europe owing to the high awareness about the disease and vaccination ,Increasing government immunization programs and  manufactures supports to provide cost-effective vaccines  is driving the growth of the rubella vaccine market in the forecast period 2020-2025.
However, Europe is estimated to grow at a highest CAGR during the forecast period 2020-2025 owing to the increasing government vaccination programs and growing investments in vaccination. Increasing healthcare expenditure, government initiatives, increasing per capita income and the expansion of vaccination programs by the government to increase prevention from infectious disease is boosting the growth of the rubella vaccine market in Europe region

Drivers – Rubella Vaccine Market
  • Increase in government focus on rubella vaccination
Increase in government focus on rubella vaccination is increasing the demand of the rubella vaccine market owing to the rising government and non-government funding for rubella vaccine development and the high prevalence of diseases. Increasing investment by companies, increasing global vaccination coverage and growing immunization programs is estimated to propel the growth of rubella vaccines market. Rubella can cause serious birth deficiencies in developing baby if a woman is infected when she is pregnant. The best method to protect against rubella and measles is measles-rubella (MR) vaccines which give long-term immunity and for this various government and organizations are conducting preventive programs.
  • Increase in the infection which results in congenital defects
Increase in the infection which results in congenital defects is increasing the demand of the rubella vaccine market owing to the increasing number of incidences and prevalence of the disease. The virus replicates in the respiratory tract and is transmitted to others via respiratory secretions through aerosolized droplets in closed areas and appearance of symptoms is 10-12 days after the infection which is usually fever. Rubella vaccine should not be given to the individuals who are on immunosuppressants as the virus can replicate and cause infections. There is no cure for congenital rubella syndrome, and it is important to prevent it and for the prevention of congenital defects MMR (measles, mumps, rubella) vaccine is given at least 28 days beforehand.

Challenges – Rubella Vaccine Market
  • Reactions related to vaccinations and insufficient yield   
Some of the factors that impede the growth of the rubella vaccine   market are reactions related to vaccinations and insufficient yield with high selectivity of human diploid cell while constructing rubella vaccines. 

Rubella Vaccine Industry Outlook
Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the Rubella Vaccine Market. In 2019, Rubella Vaccine Market share is consolidated by the top ten players present in the market. Rubella Vaccine top 10 companies are Merck & Co. Inc., GlaxoSmithKline Plc, Sanofi Aventis, Pfizer Inc., Blerna Biotech, Serum Institute of India, Astellas Pharma Inc., CSL Limited and Chiron Corporation, among others.

Acquisitions/Product Launches
  • In December 2019, Merck & Co. Inc, acquires ArQule which is famous for its targeted therapies.
  • In January 2019, GlaxoSmithKline Plc, acquires TESARO.
1. Rubella Vaccine Market - Overview
    1.1 Definitions and Scope
2. Rubella Vaccine Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by  End User
    2.3 Key trends by Distribution Channel
    2.4 Key trends by Geography
3. Rubella Vaccine Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Rubella Vaccine Market - Startup Companies Scenario (Premium)
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Rubella Vaccine Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Rubella Vaccine Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Rubella Vaccine Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Rubella Vaccine Market – By End User (Market Size –$Million/$Billion)
    8.1 Pediatric Rubella Vaccine
    8.2 Adult Rubella Vaccine
    8.3 Traveler Rubella Vaccine
9. Rubella Vaccine Market – By Distribution Channel (Market Size –$Million/$Billion)
    9.1 Hospital Pharmacies
    9.2 Drug Stores
    9.3 Retail Pharmacies
10. Rubella Vaccine Market - By Geography 
    10.1 North America
        10.1.1 U.S.
        10.1.2 Mexico
        10.1.3 Canada
    10.2 Europe
        10.2.1 U.K.
        10.2.2 France
        10.2.3 Germany
        10.2.4 Italy
        10.2.5 Spain
        10.2.6 Rest of Europe
    10.3 Asia Pacific
        10.3.1 China
        10.3.2 India
        10.3.3 Japan
        10.3.4 South Korea
        10.3.5 Australia
        10.3.6 New Zealand
        10.3.7 Rest of APAC
    10.4 Rest of the World
        10.4.1 Middle East
        10.4.2 Africa
        10.4.3 South America
11. Rubella Vaccine Market - Entropy
12. Rubella Vaccine Market – Industry/Segment Competition Landscape   (Premium) 
    12.1 Market Share Analysis
        12.1.1 Global Market Share – Key Companies
        12.1.2 Market Share by Region – Key companies
        12.1.3 Market Share by Countries – Key Companies
        12.1.4 Best Practices for Companies
13. Rubella Vaccine Market – Key Company List by Country Premium (Premium)
14. Rubella Vaccine Market Company Analysis
    14.1 Company 1
    14.2 Company 2
    14.3 Company 3
    14.4 Company 4
    14.5 Company 5
    14.6 Company 6
    14.7 Company 7
    14.8 Company 8
    14.9 Company 9
    14.10 Company 10 and more
"*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

1.Global Global Rubella Vaccine Market, By End User Market 2019-2024 ($M)
1.1 Pediatric Rubella Vaccine Market 2019-2024 ($M) - Global Industry Research
1.2 Adult Rubella Vaccine Market 2019-2024 ($M) - Global Industry Research
1.3 Traveler Rubella Vaccine Market 2019-2024 ($M) - Global Industry Research
2.Global Global Rubella Vaccine Market, By End User Market 2019-2024 (Volume/Units)
2.1 Pediatric Rubella Vaccine Market 2019-2024 (Volume/Units) - Global Industry Research
2.2 Adult Rubella Vaccine Market 2019-2024 (Volume/Units) - Global Industry Research
2.3 Traveler Rubella Vaccine Market 2019-2024 (Volume/Units) - Global Industry Research
3.North America Global Rubella Vaccine Market, By End User Market 2019-2024 ($M)
3.1 Pediatric Rubella Vaccine Market 2019-2024 ($M) - Regional Industry Research
3.2 Adult Rubella Vaccine Market 2019-2024 ($M) - Regional Industry Research
3.3 Traveler Rubella Vaccine Market 2019-2024 ($M) - Regional Industry Research
4.South America Global Rubella Vaccine Market, By End User Market 2019-2024 ($M)
4.1 Pediatric Rubella Vaccine Market 2019-2024 ($M) - Regional Industry Research
4.2 Adult Rubella Vaccine Market 2019-2024 ($M) - Regional Industry Research
4.3 Traveler Rubella Vaccine Market 2019-2024 ($M) - Regional Industry Research
5.Europe Global Rubella Vaccine Market, By End User Market 2019-2024 ($M)
5.1 Pediatric Rubella Vaccine Market 2019-2024 ($M) - Regional Industry Research
5.2 Adult Rubella Vaccine Market 2019-2024 ($M) - Regional Industry Research
5.3 Traveler Rubella Vaccine Market 2019-2024 ($M) - Regional Industry Research
6.APAC Global Rubella Vaccine Market, By End User Market 2019-2024 ($M)
6.1 Pediatric Rubella Vaccine Market 2019-2024 ($M) - Regional Industry Research
6.2 Adult Rubella Vaccine Market 2019-2024 ($M) - Regional Industry Research
6.3 Traveler Rubella Vaccine Market 2019-2024 ($M) - Regional Industry Research
7.MENA Global Rubella Vaccine Market, By End User Market 2019-2024 ($M)
7.1 Pediatric Rubella Vaccine Market 2019-2024 ($M) - Regional Industry Research
7.2 Adult Rubella Vaccine Market 2019-2024 ($M) - Regional Industry Research
7.3 Traveler Rubella Vaccine Market 2019-2024 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Rubella Vaccine Market Revenue, 2019-2024 ($M)
2.Canada Rubella Vaccine Market Revenue, 2019-2024 ($M)
3.Mexico Rubella Vaccine Market Revenue, 2019-2024 ($M)
4.Brazil Rubella Vaccine Market Revenue, 2019-2024 ($M)
5.Argentina Rubella Vaccine Market Revenue, 2019-2024 ($M)
6.Peru Rubella Vaccine Market Revenue, 2019-2024 ($M)
7.Colombia Rubella Vaccine Market Revenue, 2019-2024 ($M)
8.Chile Rubella Vaccine Market Revenue, 2019-2024 ($M)
9.Rest of South America Rubella Vaccine Market Revenue, 2019-2024 ($M)
10.UK Rubella Vaccine Market Revenue, 2019-2024 ($M)
11.Germany Rubella Vaccine Market Revenue, 2019-2024 ($M)
12.France Rubella Vaccine Market Revenue, 2019-2024 ($M)
13.Italy Rubella Vaccine Market Revenue, 2019-2024 ($M)
14.Spain Rubella Vaccine Market Revenue, 2019-2024 ($M)
15.Rest of Europe Rubella Vaccine Market Revenue, 2019-2024 ($M)
16.China Rubella Vaccine Market Revenue, 2019-2024 ($M)
17.India Rubella Vaccine Market Revenue, 2019-2024 ($M)
18.Japan Rubella Vaccine Market Revenue, 2019-2024 ($M)
19.South Korea Rubella Vaccine Market Revenue, 2019-2024 ($M)
20.South Africa Rubella Vaccine Market Revenue, 2019-2024 ($M)
21.North America Rubella Vaccine By Application
22.South America Rubella Vaccine By Application
23.Europe Rubella Vaccine By Application
24.APAC Rubella Vaccine By Application
25.MENA Rubella Vaccine By Application
26.Merck Co , Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.Glaxosmithkline Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Chiron Corporation, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.Sanofi-Aventis, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.Serum Institute Of India, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Astrazeneca Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.Berna Biotech, Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.Astellas Pharma Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.Csl Limited, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.Pfizer Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)